Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer.
Kashihara T, Nakayama Y, Okuma K, Takahashi A, Kaneda T, Katagiri M, Nakayama H, Kubo Y, Ito K, Nakamura S, Takahashi K, Inaba K, Murakami N, Saito T, Okamoto H, Itami J, Kusumoto M, Ohe Y, Igaki H.
Kashihara T, et al. Among authors: nakayama y, nakayama h.
Radiother Oncol. 2023 Mar;180:109454. doi: 10.1016/j.radonc.2022.109454. Epub 2023 Jan 11.
Radiother Oncol. 2023.
PMID: 36640944
Free article.